American pharmaceutical giant Eli Lilly has pushed back the deadline for the approval of retatrutide, a new generation of obesity drug. While two companies were given the opportunity to submit registration this year, each will now submit documentation in the first quarter of the fifth year. The reason is the need to complete the collection and analysis of production and quality data, which requires the regulation of the order.
Postponement of injections despite the fact that retatrutide achieved positive results in two other clinical trials of the fetus. According to the company, leba led to significant weight loss and improved blood sugar control in patients with obesity and so-called co-morbidities, including type 2 diabetes and cardiovascular disease. In one of the studies, patients suffering from obesity and type 2 diabetes achieved an average dream weight loss of 20.8 percent after 80 weeks, or 23 kilograms. The first group of patients usually has the biggest problems with losing weight, reports the CNBC server. The type of study followed people with severe obesity and confirmed cardiovascular disease, with and without diabetes. In this group, the diet led to an average weight loss of 22.6 percent, or about 25 kilograms over 80 weeks. Eli Lilly also stated that the preparation significantly affected selected risk factors related to cardiovascular disease. Safety profile of the once-weekly injectable preparation according to the company’s response to the previous study. The most common adverse reactions were diarrhea, nausea, and constipation. It is a side effect associated with a whole group of drugs based on the active hormone GLP-1.
Triple agonist
Retatrutide works as a triple agonist of the GLP-1, GIP and glucagon receptors, which is different from the current generation of drugs based on the tirzepatide family (GLP-1 and GIP), which includes the drugs Mounjaro and Zepbound. According to current data, the first combination of these mechanisms could have a significant effect on the regulation of appetite and the feeling of satiety, not currently available therapy. For Eli Lilly, retatrutide is a key drug in its bid to gain market share over Danish competitor Novo Nordisk in the growing market for weight loss and diabetes drugs. TD Cowen analysts estimated this year that retatrutide sales could reach $3.8 billion by 2030.